Recursion Pharmaceuticals, Inc. Class A (RXRX) Dividend History

Company News

• Jensen Huang's Nvidia Owns 6 Stocks. Here's the Best of the Bunch.

  Nvidia has invested in six AI-related companies, including CoreWeave, Arm Holdings, and Applied Digital, leveraging its market leadership in GPU technology to support and expand the AI sector.

  The Motley Fool

  Featured Companies: APLD CRWV NBIS
• Why Is Microcap Rallybio Stock Trading Higher On Tuesday?

  Rallybio Corporation sold its interest in REV102, a preclinical ENPP1 inhibitor for hypophosphatasia, to Recursion Pharmaceuticals for up to $25 million, extending its cash runway into mid-2027.

  Benzinga

  Featured Companies: RLYB
• Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden

  Recursion's investigational drug REC-4881 showed a median 43% reduction in polyp burden in a Phase 2 study for Familial Adenomatous Polyposis (FAP), a rare genetic disorder. The early safety profile was generally consistent with prior MEK1/2 inhibitors.

  GlobeNewswire Inc.
• Recursion Pharmaceuticals director sells $83.7k in stock - Investing.com

  Recursion Pharmaceuticals director Blake Borgeson sold 11,447 shares of the company's Class A common stock for $83,734. The sale was part of a pre-arranged trading plan. Recursion Pharmaceuticals is a biotechnology company focused on leveraging advanced technologies to enhance drug discovery and treatment development.

  Investing.com
• Recursion Pharmaceuticals (RXRX) Surpasses Market Returns: Some Facts Worth Knowing

  Recursion Pharmaceuticals (RXRX) reachead $9.38 at the closing of the latest trading day, reflecting a +0.43% change compared to its last close.

  Zacks Investment Research